The combination of irinotecan plus carboplatin has antitumour activity in non-small-cell lung cancer (NSCLC)

Author：  

Publisher： Adis International

ISSN： 1173-8324

Source： Inpharma, Vol.1, Iss.1473, 2005-01, pp. : 14-14

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Activity of carboplatin in patients with advanced non-small cell lung cancer pre-treated with a non-platinum combination

By Esteban-Gonzalez Emilio   Fernández Yolanda   Villanueva Noemí   Fra Joaquin   Muñiz Isabel   Palacio Isabel   Vieitez Jose   Uña Esther   Mareque Beatriz   Lacave Angel  

Investigational New Drugs, Vol. 23, Iss. 6, 2005-12 ,pp. : 597-601

Springer Publishing Company

Access to resources Recommend Favorite

BMS 184476 shows "remarkable activity" in patients with previously-treated non-small-cell lung cancer (NSCLC)

By  

Inpharma, Vol. 1, Iss. 1486, 2005-01 ,pp. : 8-8

Adis International

Access to resources Recommend Favorite

Combination Chemotherapy with Docetaxel and Carboplatin for Advanced Non-Small Cell Lung Cancer

By Schuette W.  

Clinical Drug Investigation, Vol. 21, Iss. 3, 2001-03 ,pp. : 161-168

Adis International

Access to resources Recommend Favorite

Bortezomib with or without docetaxel has modest activity for refractory or recurrent advanced non-small-cell lung cancer

By  

Inpharma, Vol. 1, Iss. 1565, 2006-01 ,pp. : 12-12

Adis International

Access to resources Recommend Favorite

Vandetanib has value in non-small-cell lung cancer

By  

Inpharma, Vol. 1, Iss. 1544, 2006-01 ,pp. : 9-9

Adis International

Access to resources Recommend Favorite